{"id":1977,"date":"2013-01-17T22:49:58","date_gmt":"2013-01-17T13:49:58","guid":{"rendered":"\/sawamura\/blog\/?p=1977"},"modified":"2025-01-10T16:42:24","modified_gmt":"2025-01-10T07:42:24","slug":"immunotherap","status":"publish","type":"post","link":"https:\/\/plaza.umin.ac.jp\/sawamura\/blog\/glioma\/immunotherap\/","title":{"rendered":"\u514d\u75ab\u6cbb\u7642\u3068\u764c\u30ef\u30af\u30c1\u30f3"},"content":{"rendered":"<p>\u6628\u4eca\u306eNHK\u306e\u5831\u9053\u306a\u3069\u306e\u5f71\u97ff\u3067\uff0c\u305f\u304f\u3055\u3093\u306e\u304c\u3093\u60a3\u8005\u3055\u3093\u304c\u514d\u75ab\u6cbb\u7642\u3092\u6c42\u3081\u308b\u3088\u3046\u306b\u306a\u308a\u307e\u3057\u305f\u3002\u307e\u305f\uff0c\u96d1\u8a8c\u3084\u30cd\u30c3\u30c8\u4e0a\u3067\u3082\uff0c\u514d\u75ab\u6cbb\u7642\u3092\u53d7\u3051\u308b\u3053\u3068\u306b\u3088\u3063\u3066\u304c\u3093\u306e\u9032\u884c\u3092\u6b62\u3081\u308b\u3053\u3068\u304c\u3067\u304d\u3066\uff0c\u3064\u3089\u3044\u5236\u304c\u3093\u5264\u306e\u5316\u5b66\u7642\u6cd5\u304b\u3089\u89e3\u653e\u3055\u308c\u3066\uff0c\u65e5\u5e38\u751f\u6d3b\u306b\u623b\u308b\u3053\u3068\u304c\u3067\u304d\u305f\u3068\u3044\u3046\u4e8b\u4f8b\u3092\u3042\u3052\u305f\u308a\u3057\u3066\u3044\u307e\u3059\u3002\u3055\u3089\u306b\uff0c\u672b\u671f\u304c\u3093\u3092\u6cbb\u3057\u305f\u308a\u3059\u308b\u52b9\u679c\u304c\u3042\u308b\u3068\u3044\u3046\u3088\u3046\u306a\u55a7\u4f1d\u3092\u3057\u3066\u3044\u307e\u3059\u3002News Week\u306a\u3069\u306e\u6a29\u5a01\u3042\u308b\u96d1\u8a8c\u3067\u3082\u53d6\u308a\u4e0a\u3052\u3089\u308c\u307e\u3057\u305f\u3002\u3053\u306e\u3088\u3046\u306a\u5831\u9053\u304c\u7d9a\u304f\u3068\uff0c\u304c\u3093\u306e\u514d\u75ab\u6cbb\u7642\u3092\u77e5\u3089\u306a\u3044\u4e00\u822c\u306e\u65b9\u3084\uff0c\u5834\u5408\u306b\u3088\u3063\u3066\u306f\u304a\u533b\u8005\u3055\u3093\u3082\u4fe1\u3058\u3066\u3057\u307e\u3046\u304b\u3082\u3057\u308c\u307e\u305b\u3093\u3002\u884c\u304f\u5148\u4e0d\u660e\u3067\u3059&#8212;-\u3002<\/p>\n<h5>\u8133\u816b\u760d\u306e\u4e16\u754c\u3067\u306f\uff0c\u3053\u306e50\u5e74\u306e\u9593\u306b\uff0c\u514d\u75ab\u6cbb\u7642\u306f\uff0c\u6ce1\u306e\u3088\u3046\u306b\u51fa\u3066\u306f\u6d88\u3048\u3066\u3044\u304d\u307e\u3057\u305f<\/h5>\n<hr \/>\n<h4>\u3044\u307e\u5927\u5207\u306a\u3053\u3068<\/h4>\n<p>\u8133\u816b\u760d\uff0c\u60aa\u6027\u30b0\u30ea\u30aa\u30fc\u30de\uff0c\u5c0f\u5150\u8133\u816b\u760d\u306a\u3069\u306a\u3069\uff0c\u3069\u306e\u3088\u3046\u306a\u8133\u816b\u760d\u75c5\u540d\u3067\u3042\u3063\u3066\u3082\uff0c<strong><span style=\"color: #000080;\">\u73fe\u6642\u70b9\u3067\u306e\u65b9\u6cd5\u3067\u306f\uff0c\u514d\u75ab\u6cbb\u7642\u306e\u52b9\u679c\u306f\u3042\u308a\u307e\u305b\u3093<\/span><\/strong>\u3002\u6709\u540d\u306a\u5927\u5b66\u304c\uff0c\u30ef\u30af\u30c1\u30f3\u6cbb\u7642\u306e\u6cbb\u9a13\u3092\u3057\u3066\u3082\u3044\u307e\u3059\u304c\uff0c\u52b9\u679c\u306f\u306a\u3044\u3068\u8003\u3048\u3066\u9593\u9055\u3044\u306f\u3042\u308a\u307e\u305b\u3093\u3002\u3067\u3059\u304b\u3089\u6700\u65b0\u306e\u6cbb\u7642\u6cd5\u3060\u3068\u304b\u9ad8\u5ea6\u5148\u9032\u533b\u7642\u3068\u304b\u3044\u3046\u6587\u8a00\u306b\u60d1\u308f\u3055\u308c\u3066\u5b89\u6613\u306b\u9ad8\u984d\u306a\u6cbb\u7642\u3092\u53d7\u3051\u306a\u3044\u3088\u3046\u306b\u3057\u307e\u3057\u3087\u3046\u3002\u8133\u816b\u760d\u306e\u514d\u75ab\u6cbb\u7642\u306b\u79d1\u5b66\u7684\u306b\u8a3c\u660e\u3055\u308c\u305f\u52b9\u679c\u306f\u306a\u3044\u306e\u3067\u3059\u3002<\/p>\n<p>\u7279\u306b<span style=\"color: #000080;\"><strong>\u6c17\u3092\u3064\u3051\u306a\u3051\u308c\u3070\u306a\u3089\u306a\u3044\u306e\u306f\uff0c\u6c11\u9593\u56e3\u4f53\u3042\u308b\u3044\u306f\u6c11\u9593\u75c5\u9662\u306e\u5ba3\u4f1d\u3057\u3066\u3044\u308b\u514d\u75ab\u6cbb\u7642<\/strong><\/span>\u3067\u3059\u3002\u514d\u75ab\u8ce6\u6d3b\u5264\uff08\u514d\u75ab\u306e\u80fd\u529b\u3092\u9ad8\u3081\u308b\u85ac\u5264\u3084\u98df\u54c1\uff09\uff0c\u30ef\u30af\u30c1\u30f3\uff0c\u6a39\u72b6\u7a81\u8d77\u7d30\u80de\uff0c\u30ea\u30f3\u30d1\u7403\u6d3b\u6027\u5316\u306a\u3069\u306a\u3069\uff0c\u69d8\u3005\u306a \u3082\u306e\u304c\u3042\u308a\u307e\u3059\u304c\uff0c\u304a\u91d1\u304c\u304b\u304b\u308b\u3068\u3044\u3046\u3053\u3068\u3067\u3059\u3002\u6cbb\u3089\u306a\u3044\u3068\u3044\u308f\u308c\u305f\u8133\u816b\u760d\u306e\u60a3\u8005\u3055\u3093\u306e\u5bb6\u65cf\u304c\uff0c\u5927\u5207\u306a\u4eba\u3092\u52a9\u3051\u308b\u305f\u3081\u306b\u7cbe\u4e00\u676f\u306e\u304a\u91d1\u3092\u4f7f\u3046\u3053\u3068\u3092\u308f\u304b\u3063\u3066\u3044\u3066\u306e\u884c\u70ba\u3092\u3057\u3066\u3044\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n<p>\u81ea\u5bb6\u304c\u3093\u30ef\u30af\u30c1\u30f3\u3082\u30cd\u30c3\u30c8\u3067\u5ba3\u4f1d\u3055\u308c\u3066\u3044\u307e\u3059\u304c\uff0c\u30b0\u30ea\u30aa\u30fc\u30de\u306b\u52b9\u304f\u3068\u3044\u3046\u4e8b\u5b9f\u306f\u3042\u308a\u307e\u305b\u3093\u306e\u3067\u6ce8\u610f\u3057\u3066\u304f\u3060\u3055\u3044\u30022023\u5e74\u672b\uff0cDCVax\u00ae-L\u304c\u82f1\u56fd\u3067\u81e8\u5e8a\u4f7f\u7528\u7533\u8acb\u304c\u306a\u3055\u308c\u308b\u3088\u3046\u3067\u3059\u3002<\/p>\n<h5>\u4ee5\u4e0b\u306f\u4e3b\u306a\u60c5\u5831<\/h5>\n<h4>DCVax-L\u514d\u75ab\u6cbb\u7642\u306e\u81e8\u5e8a\u7b2c\uff13\u76f8\u8a66\u9a13<\/h4>\n<p><span class=\"meta-authors--limited\"><span class=\"wi-fullname brand-fg\">Linda M:\u00a0<\/span><\/span>Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma<span class=\"subtitle\">A Phase 3 Prospective Externally Controlled Cohort Trial.\u00a0<\/span><span class=\"meta-citation-journal-name\">JAMA Oncol. <\/span><span class=\"meta-citation\">2023<\/span><br \/>\n\u4e0a\u8a18\u96d1\u8a8c\u306b\u767a\u8868\u3055\u308c\u308b\u524d\u306b\uff0c2022\u5e74\u306e\u30cb\u30e5\u30fc\u30e8\u30fc\u30af\u306e\u5b66\u4f1a\u3067\u7b2c3\u76f8\u8a66\u9a13\u306e\u7d50\u679c\u304c\u767a\u8868\u3055\u308c\u307e\u3057\u305f\u3002\u7d50\u679c\u306f\u540c\u3058\u3067\u3059\u3002\u6a39\u72b6\u7a81\u8d77\u7d30\u80de\u3092\u53d6\u308a\u51fa\u3057\u3066\u8ce6\u6d3b\u5316\u3057\u3066\u8155\u306b\u76ae\u4e0b\u6ce8\u5c04\u3067\u623b\u3059\u3068\u3044\u3046\u514d\u75ab\u6cbb\u7642\u3067\u3059\u3002\u521d\u767a\u81a0\u82bd\u816b232\u4f8b\u3067\u8a66\u9a13\u304c\u884c\u308f\u308c\u307e\u3057\u305f\u3002\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u306fexternal control 1,366\u4f8b\u3067\u3059\u3002<span style=\"color: #000080;\"><strong>\u751f\u5b58\u671f\u9593\u4e2d\u592e\u5024\u306f\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u306e16.5\u30f6\u6708\u306b\u5bfe\u3057\u3066\uff0cDCVax\u3067\u306f19.3\u30f6\u6708\u3078\u5ef6\u9577\u3057\u307e\u3057\u305f<\/strong><\/span>\u3002\u3053\u306e\u5dee\u306f\u7d71\u8a08\u5b66\u7684\u306b\u6709\u610f\u3067\u3042\u308b\u3068\u767a\u8868\u3055\u308c\u3066\u3044\u307e\u3059\u30025\u5e74\u751f\u5b58\u5272\u5408\u306f\u305d\u308c\u305e\u308c5.7%\u306813\uff05\u3067\u3059\u3002<br \/>\n\u554f\u984c\u306fexternal control\u3068\u3057\u3066\u53d6\u3089\u308c\u305f\u4f8b\u304c\uff0c\u6587\u732e\u30672013\u5e74\u306b\u767a\u8868\u3055\u308c\u305f411\u4f8b\u306a\u3069\u3092\u542b\u3080\u3053\u3068\u3067\u3059\u3002\u9006\u7b97\u3059\u308c\u3070\uff0c\u6cbb\u9a13\u958b\u59cb\u6642\u304b\u3089\u9451\u307f\u306620\u5e74\u4ee5\u4e0a\u524d\u306b\u6cbb\u7642\u3055\u308c\u305f\u4f8b\u3092\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3068\u3057\u3066\u7528\u3044\u3066\u3044\u308b\u3053\u3068\u3067\u3059\u3002\u7d50\u679c\u306e\u8a55\u4fa1\u306f\u8a71\u306b\u306a\u3089\u306a\u3044\u30ec\u30d9\u30eb\u3067\u3059\u3002<\/p>\n<h4>\u30c7\u30ea\u30bf\u30af\u30c8\uff1a\u304c\u3093\u6cbb\u7642\u30a6\u30a3\u30eb\u30b9\u7642\u6cd5\u306e\u4f9b\u7d66\u5236\u9650<\/h4>\n<p>\u7b2c\u4e00\u4e09\u5171\u304c\u751f\u7523\u3057\u3066\u3044\u308b\u88fd\u54c1\u3067\u3059\u304c\u6cbb\u9a13\u5b9f\u65bd\u65bd\u8a2d\u3067\u4f7f\u7528\u3067\u304d\u308b\u306f\u305a\u3067\u3057\u305f\uff0c\u3057\u304b\u3057\u88fd\u54c1\u306e\u4f9b\u7d66\u306b\u5236\u9650\u304c\u3042\u308a\uff0c2022\u5e745\u6708\u6642\u70b9\u3067\u306f\u6771\u4eac\u5927\u5b66\u3067\u9069\u5fdc\u3068\u306a\u308b\u60a3\u8005\u3055\u3093\u306e\u307f\u306b\u4f7f\u7528\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n<h4>\u653e\u5c04\u7dda\u3068\u30aa\u30d6\u30b8\u30fc\u30dc\uff08\u30cb\u30dc\u30eb\u30de\u30d6\uff09\u306e\u4f75\u7528\u306b\u5229\u70b9\u306f\u306a\u3044<\/h4>\n<div class=\"title-wrap\">\n<p class=\"wi-article-title article-title-main accessible-content-title at-articleTitle\"><span class=\"al-author-name js-flyout-wrap\">Omuro A:\u00a0<\/span>Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated <em>MGMT<\/em>Promoter: An International Randomized Phase 3 Trial. Neuro Oncol 2022<br \/>\n560\u540d\u306e\u81a0\u82bd\u816b\u60a3\u8005\u3055\u3093\u3067\u81e8\u5e8a\u7b2c3\u76f8\u8a66\u9a13\u304c\u884c\u308f\u308c\u307e\u3057\u305f(CheckMate 498)\u3002\u30aa\u30d6\u30b8\u30fc\u30dc\u3068\u653e\u5c04\u7dda\u6cbb\u7642\u306e\u7d44\u307f\u5408\u308f\u305b\u306f\uff0c\u6a19\u6e96\u6cbb\u7642\u3067\u3042\u308b\u30c6\u30e2\u30be\u30ed\u30de\u30a4\u30c9\u3068\u653e\u5c04\u7dda\u6cbb\u7642\u3088\u308a\u5168\u751f\u5b58\u5272\u5408\u3092\u6539\u5584\u3057\u307e\u305b\u3093\u3067\u3057\u305f\u3002<\/p>\n<\/div>\n<h4>\u65e5\u672c\u3067\u30c6\u30bb\u30eb\u30d1\u30c4\u30ec\u30d6\uff08\u5546\u54c1\u540d\u30c7\u30ea\u30bf\u30af\u30c8\uff0c\u30a6\u30a3\u30eb\u30b9\u7642\u6cd5\uff09\u306e\u4f7f\u7528\u304c\u8a31\u53ef\u3055\u308c\u307e\u3057\u305f<\/h4>\n<p>\u3044\u308f\u3086\u308b<span style=\"color: #000080;\"><strong>\u30a6\u30a3\u30eb\u30b9\u7642\u6cd5<\/strong><\/span>\u3068\u547c\u3070\u308c\u308b\u3082\u306e\u3067\u3059\uff0c2021\u5e748\u6708\u306b\u518d\u751f\u533b\u7642\u7b49\u88fd\u54c1\u3068\u3057\u3066\u8a8d\u53ef\u3055\u308c\u307e\u3057\u305f\u3002\u5358\u7d14\u30d8\u30eb\u30da\u30b9\u30a6\u30a4\u30eb\u30b91\u578b\u3092\u4f7f\u7528\u3057\u307e\u3059\u304c\uff0c\u6b63\u5e38\u7d30\u80de\u3067\u306e\u8907\u88fd\u306b\u5fc5\u8981\u306a2\u306e\u907a\u4f1d\u5b50\u3092\u6b20\u5931\u3057\u3066\u3044\u308b\u306e\u3067\u6b63\u5e38\u8133\u7d30\u80de\u306e\u4e2d\u3067\u306f\u5897\u3048\u307e\u305b\u3093\u3002\u3055\u3089\u306bICP6\u907a\u4f1d\u5b50\u3092\u4e0d\u6d3b\u5316\u3057\u305f\u907a\u4f1d\u5b50\u7d44\u63db\u3048\u3092\u4e3b\u6210\u5206\u3068\u3059\u308b\u88fd\u54c1\u3067\u3059\u3002\u305d\u308c\u3092\u81a0\u82bd\u816b\u306e\u5185\u90e8\u306b\u76f4\u63a5\u6ce8\u5165\u3059\u308b\u3053\u3068\u3067\u3001\u816b\u760d\u7d30\u80de\u3067\u9078\u629e\u7684\u306b\u30a6\u30a3\u30eb\u30b9\u304c\u8907\u88fd\u3057\u3001\u611f\u67d3\u3057\u305f\u81a0\u82bd\u816b\u7d30\u80de\u3092\u7834\u58ca\u3057\u3066\u6bba\u7d30\u80de\u52b9\u679c\u3092\u793a\u3057\u307e\u3059\u3002\u52a0\u3048\u3066\uff0c\u816b\u760d\u53cd\u5fdc\u6027T\u7d30\u80de CTL \u306e\u8a98\u5c0e\u306b\u3088\u308a\u6297\u816b\u760d\u514d\u75ab\u52b9\u679c\u3092\u793a\u3059\u3053\u3068\u304c\u7406\u8ad6\u7684\u306b\u671f\u5f85\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u8133\u816b\u760d\u306e\u5185\u90e8\u306b\u5916\u79d1\u7684\u51e6\u7f6e\uff08\u5b9a\u4f4d\u8133\u624b\u8853\uff09\u3067\uff0c1\u56de\u3042\u305f\u308a1mL\u3092\u76f4\u63a5\u6295\u4e0e\u3057\u307e\u3059\u3002\u539f\u5247\u3068\u3057\u3066\u30011\u56de\u76ee\u30682\u56de\u76ee\u306f5\uff5e14 \u65e5\u306e\u9593\u9694\u30013\u56de\u76ee\u4ee5\u964d\u306f4\u9031\u9593\u306e\u9593\u9694\u3067\u6295\u4e0e\u3067\uff0c6\u56de\u307e\u3067\u3067\u3059\u3002\u81e8\u5e8a\u7b2c2\u76f8\u8a66\u9a13\u306f19\u4f8b\u306e\u518d\u767a\u81a0\u82bd\u816b\u306e2018\u5e74\u6642\u70b9\u3067\u306e\u89e3\u6790\u3067\u306fPFS \u7121\u5897\u60aa\u751f\u5b58\u671f\u9593\u306f30%\u307b\u3069\u3068\u5831\u544a\u3055\u308c\u3066\u3044\u307e\u3059\u3002<br \/>\n<span style=\"color: #ff0000;\"><strong>\uff08\u6ce8\u610f\uff09\u307e\u3060\u3054\u304f\u5c0f\u3055\u306a\u65e9\u671f\u306e\u81e8\u5e8a\u8a66\u9a13\u3092\u7d42\u3048\u305f\u3070\u304b\u308a\u30672022\u5e74\u3067\u3082\u6cbb\u9a13\u6bb5\u968e\u306e\u6cbb\u7642\u6cd5\u3067\u3059\uff0c\u6709\u52b9\u6027\u306f\u8a3c\u660e\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002\u304b\u306a\u308a\u5c0f\u3055\u306a\u81a0\u82bd\u816b\u306b\u3057\u304b\u6709\u52b9\u6027\u306f\u306a\u3044\u3082\u306e\u3068\u8003\u3048\u3089\u308c\u3066\u3044\u307e\u3059\u3057\uff0c\u526f\u4f5c\u7528\u3068\u3057\u3066\u306e\u8133\u6d6e\u816b\u304c\u554f\u984c\u3068\u306a\u308b\u3082\u306e\u3067\u3059\u3002<\/strong><\/span><\/p>\n<h4>HSV-1 G207\u514d\u75ab\u7642\u6cd5<\/h4>\n<p><span class=\"title_default\">Gregory K: Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. N Engl J Med, 2021<br \/>\n\u6b63\u5e38\u8133\u7d30\u80de\u3067\u306f\u5897\u6b96\u3067\u304d\u306a\u3044\u3068\u3044\u3046\u6027\u8cea\u3092\u3082\u3064\u5358\u7d14\u30d8\u30eb\u30da\u30b9\u30bf\u30a4\u30d71 (oncolytic HSV-1 G207) \u3092\u7528\u3044\u305f\u30a6\u30a3\u30eb\u30b9\u514d\u75ab\u7642\u6cd5\u306e\u81e8\u5e8a\u7b2c\uff11\u76f8\u8a66\u9a13\u306e\u7d50\u679c\u3067\u3059\u3002\u518d\u767a\u3042\u308b\u3044\u306f\u9032\u884c\u6027\u30c6\u30f3\u30c8\u4e0a\u60aa\u6027\u795e\u7d4c\u81a0\u816b\u306e\u5c0f\u5150\uff087-18\u6b73\uff0912\u4eba\u304c\u6cbb\u7642\u3092\u53d7\u3051\u307e\u3057\u305f\u3002\u816b\u760d\u90e8\u5206\u306b4\u672c\u306e\u30ab\u30c6\u30fc\u30c6\u30eb\u3092\u633f\u5165\u3057\uff0c\u7fcc\u65e5\u306b6\u6642\u9593\u304b\u3051\u3066G207\u30a6\u30a3\u30eb\u30b9\u3092\u6ce8\u5165\u3057\u307e\u3059\u3002\u30b3\u30db\u30fc\u30c83\u30684\u3067\u306f\uff0c24\u6642\u9593\u5f8c\u306b5\u30b0\u30ec\u30a4\u306e\u5c40\u6240\u653e\u5c04\u7dda\u6cbb\u7642\u304c\u52a0\u3048\u3089\u308c\u307e\u3057\u305f\u300212\u4eba\u4e2d11\u4eba\u3067\uff0c\u753b\u50cf\u4e0a\uff0c\u75c5\u7406\u5b66\u7684\u3042\u308b\u3044\u306f\u81e8\u5e8a\u7684\u306a\u53cd\u5fdc\u304c\u8a8d\u3081\u3089\u308c\u305f\u3068\u306e\u3053\u3068\u3067\u3059\u3002OS\u306f12\u30f6\u6708\uff0c11\u4eba\u4e2d\u306e4\u4eba\u304c\u6295\u4e0e\u5f8c18\u30f6\u6708\u3067\u751f\u5b58\u3057\u3066\u3044\u307e\u3057\u305f\u3002G207\u306f\u816b\u760d\u5185\u6d78\u6f64\u30ea\u30f3\u30d1\u7403\u306e\u6570\u3092\u5897\u52a0\u3055\u305b\u305f\u3068\u306e\u7d50\u679c\u3067\u3059\u3002<br \/>\n\u300c\u6ce8\u610f\u70b9\u300d\u8aad\u307f\u9593\u9055\u3048\u305d\u3046\u306a\u306e\u3067\u3059\u304c\uff0c\u81e8\u5e8a\u52b9\u679c\u304c\u3042\u308b\u3068\u306f\u66f8\u3044\u3066\u3042\u308a\u307e\u305b\u3093\u3002<\/span><\/p>\n<h4>VB-111\u306e\u6709\u52b9\u6027\u306f\u306a\u3044<\/h4>\n<p><span class=\"docsum-authors full-authors\">Cloughesy TF:\u00a0<\/span>A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). <span class=\"docsum-journal-citation full-journal-citation\">Neuro Oncol 2020<br \/>\n\u81e8\u5e8a\u7b2c\uff13\u76f8\u5927\u898f\u6a21\u7121\u4f5c\u70ba\u8a66\u9a13\u3067\u3059\u3002256\u4eba\u306e\u518d\u767a\u81a0\u82bd\u816b\u306e\u60a3\u8005\u3055\u3093\u306b\uff0cVB-111\u306e\u52b9\u679c\u304c\u8a66\u3055\u308c\u307e\u3057\u305f\u304c\u6709\u52b9\u6027\u306f\u3042\u308a\u307e\u305b\u3093\u3067\u3057\u305f\u3002VB-111\u306f\uff0c\u30a2\u30c7\u30ce\u30a6\u30a3\u30eb\u30b9 replication defficient adenovirus5 \u3092\u7528\u3044\u305f\u907a\u4f1d\u5b50\u6cbb\u7642\u3067\u3059\u3002\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3092\u30a2\u30dd\u30c8\u30fc\u30b7\u30b9\u306b\u8a98\u5c0e\u3057\u3066\u816b\u760d\u865a\u8840\u3092\u8d77\u3053\u3059\uff0c\u6297\u816b\u760d\u514d\u75ab\u3092\u8ce6\u6d3b\u3057\u3066\u816b\u760d\u5185\u3078\u306eT\u7d30\u80de\u8a98\u5c0e\u3092\u8a08\u308b\u3068\u3044\u3046\u69cb\u60f3\u3067\u3059\u3002\u5b9f\u81e8\u5e8a\u3067\u306f\uff0c\u816b\u760d\u514d\u75ab\u306f\u8ce6\u6d3b\u3055\u308c\u306a\u304b\u3063\u305f\u3068\u3044\u3046\u7d50\u679c\u3067\u3059\u3002<\/span><\/p>\n<h4>\u518d\u767a\u81a0\u82bd\u816b\u306b\u30aa\u30d6\u30b8\u30fc\u30dc (\u30cb\u30dc\u30eb\u30de\u30d6)\u306e\u6709\u52b9\u6027\u306f\u306a\u3044<\/h4>\n<div class=\"meta-article-title-wrap\">\n<p class=\"meta-article-title \"><span class=\"meta-authors--limited\"><span class=\"wi-fullname brand-fg\">Reardon DA:\u00a0<\/span><\/span>Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma<span class=\"subtitle\">The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol, 2020<br \/>\n369\u540d\u306e\u518d\u767a\u81a0\u82bd\u816b\u60a3\u8005\u3055\u3093\u3067\u7b2c\uff13\u76f8\u8a66\u9a13\u304c\u884c\u308f\u308c\u307e\u3057\u305f\u3002\u30a2\u30d0\u30b9\u30c1\u30f3\u306b\u512a\u308b\u6709\u52b9\u6027\u306f\u8a8d\u3081\u3089\u308c\u307e\u305b\u3093\u3067\u3057\u305f\u3002<\/span><\/p>\n<\/div>\n<h4>\u30aa\u30d6\u30b8\u30fc\u30dc\u306fMGMT\u30e1\u30c1\u30ec\u30fc\u30b7\u30e7\u30f3\u306e\u3042\u308b\u521d\u767a\u81a0\u82bd\u816b\u306b\u306f\u6709\u52b9\u3067\u306f\u306a\u3044<\/h4>\n<p class=\"null\">2019\u5e746\u6708\u306e\u60c5\u5831\u3067\u3059\u3002\u521d\u767a\u81a0\u82bd\u816b\u306b\u5bfe\u3059\u308b\u30aa\u30d6\u30b8\u30fc\u30dc\u306e\u81e8\u5e8a\u7b2c\uff13\u76f8\u8a66\u9a13 (CheckMate-548) \u306e\u7d50\u679c\u3067\uff0c\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593\u3092\u5ef6\u9577\u3057\u306a\u3044\u3068\u5831\u544a\u3055\u308c\u307e\u3057\u305f\u3002<\/p>\n<h4>Toca 5(Toca 511 and Toca FC)\u306f\u6709\u52b9\u3067\u306f\u306a\u3044<\/h4>\n<p>2019\u5e749\u6708\u306e\u60c5\u5831\u3067\u3059\u3002\u30b0\u30ea\u30aa\u30fc\u30de\u7d30\u80de\u3060\u3051\u306b\u9078\u629e\u7684\u306b\u611f\u67d3\u3059\u308b\u3068\u3044\u3046\u30a6\u30a3\u30eb\u30b9\u30d9\u30af\u30bf\u30fc\u3092\u5229\u7528\u3059\u308b\u514d\u75ab\u6cbb\u7642\u304c\u8a66\u3055\u308c\u307e\u3057\u305f\u3002\u9ad8\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de\u306b\u5bfe\u3057\u3066\u884c\u308f\u308c\u305f\u81e8\u5e8a\u7b2c3\u76f8\u306e\u7121\u4f5c\u70ba\u5927\u898f\u6a21\u8a66\u9a13\u306e\u7d50\u679c\u3067\u3059\u3002\u751f\u5b58\u671f\u9593\u306e\u5ef6\u9577\u306f\u3042\u308a\u307e\u305b\u3093\u3067\u3057\u305f\u3002<\/p>\n<h4>\u30aa\u30d6\u30b8\u30fc\u30dc\u306f\u81a0\u82bd\u816b\u306b\u306f\u6709\u52b9\u3067\u306f\u306a\u3044<\/h4>\n<p class=\"null\">2019\u5e746\u6708\u306e\u60c5\u5831\u3067\u3059\u3002\u521d\u767a\u81a0\u82bd\u816b\u306b\u5bfe\u3059\u308b\u30aa\u30d6\u30b8\u30fc\u30dc\u306e\u81e8\u5e8a\u7b2c\uff13\u76f8\u8a66\u9a13 Nivolumab GBM study (CheckMate-498) \u306e\u6700\u7d42\u7d50\u679c\u306f\uff0c\u751f\u5b58\u671f\u9593\u3092\u5ef6\u9577\u3057\u306a\u3044\u3068\u3044\u3046\u30cd\u30ac\u30c6\u30a3\u30d6\u306a\u7d50\u679c\u3067\u3057\u305f\u3002<\/p>\n<h4>\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\uff1a\u65b0\u305f\u306a\u514d\u75ab\u6cbb\u7642<\/h4>\n<p><span class=\"highlight\">Cloughesy TF, et al.: Neoadjuvant<\/span> <span class=\"highlight\">anti-PD-1<\/span> <span class=\"highlight\">immunotherapy<\/span> <span class=\"highlight\">promotes<\/span> a <span class=\"highlight\">survival<\/span> <span class=\"highlight\">benefit<\/span> with <span class=\"highlight\">intratumoral<\/span> and <span class=\"highlight\">systemic<\/span><span class=\"highlight\">immune<\/span> <span class=\"highlight\">responses<\/span> in <span class=\"highlight\">recurrent<\/span> <span class=\"highlight\">glioblastoma<\/span>.\u00a0<span role=\"menubar\">Nat Med.<\/span> 2019<br \/>\n\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0 (Keytruda)\u306f\uff0c\u30da\u30e0\u30d6\u30ed\u30ea\u30ba\u30de\u30d6\uff08Pembrolizumab)\u3068\u3044\u3046\u6297\u4f53\u3067\uff0cPD-1\u963b\u5bb3\u5264\u3068\u3044\u308f\u308c\u307e\u3059\u3002\u65e5\u672c\u3067\u3082\u4fdd\u967a\u53ce\u8f09\u3055\u308c\u300c\u304c\u3093\u5316\u5b66\u7642\u6cd5\u5f8c\u306b\u5897\u60aa\u3057\u305f\u9032\u884c\u30fb\u518d\u767a\u306e\u9ad8\u983b\u5ea6\u30de\u30a4\u30af\u30ed\u30b5\u30c6\u30e9\u30a4\u30c8\u4e0d\u5b89\u5b9a\u6027\uff08MSI-High\uff09\u3092\u6709\u3059\u308b\u56fa\u5f62\u764c\uff08\u6a19\u6e96\u7684\u306a\u6cbb\u7642\u304c\u56f0\u96e3\u306a\u5834\u5408\u306b\u9650\u308b\uff09\u300d\u306b\u4f7f\u7528\u8a31\u53ef\u304c\u3042\u308a\u307e\u3059\u3002<br \/>\n35\u4eba\u306e\u518d\u767a\u81a0\u82bd\u816b\u3078\u306e\u6295\u4e0e\u5831\u544a\u304c\u30cd\u30a4\u30c1\u30e3\u30fc\u306b\u767a\u8868\u3055\u308c\u307e\u3057\u305f\u3002\u624b\u8853\u3067\u6458\u51fa\u3067\u304d\u308b\u81a0\u82bd\u816b\u304c\u3042\u308b\u3068\u3044\u3046\u3053\u3068\u304c\u6761\u4ef6\u3067\u3059\u3002\u7121\u4f5c\u70ba\u306b\u60a3\u8005\u3055\u3093\u304c\u5206\u3051\u3089\u308c\uff0c\u624b\u8853\u524d\u306b\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0 (neoadjuvant pembrolizumab) \u3092\u6295\u4e0e\u3057\u305f\u60a3\u8005\u3055\u3093\u3067\u6709\u610f\u306a\u5168\u751f\u5b58\u671f\u9593\u306e\u5ef6\u9577\uff08\u4e2d\u592e\u5024\u3067417\u65e5\uff09\u304c\u3042\u3063\u305f\u3068\u306e\u3053\u3068\u3067\u3059\u3002\u6458\u51fa\u3057\u305f\u816b\u760d\u5185\u3067\u306f\uff0cupregulation of T cell\u2013 and interferon-\u03b3-related gene expression\u304c\u3042\u308a\uff0cdownregulation of cell-cycle-related gene expression \u304c\u898b\u3089\u308c\u307e\u3057\u305f\u3002\u6297\u816b\u760d\u6d3b\u6027\u3092\u3082\u3064T\u7d30\u80de\u7cfb\u306e\u514d\u75ab\u8ce6\u6d3b\u3068\u816b\u760d\u5897\u6b96\u306e\u6291\u5236\u304c\u3042\u3063\u305f\u3089\u3057\u3044\u3068\u306e\u7d50\u679c\u3067\u3059\u3002<br \/>\n\u300c\u89e3\u8aac\u300d\u816b\u760d\u7d44\u7e54\u3068\u672b\u68a2\u8840\u5185\u3067\u751f\u3058\u305f\u73fe\u8c61\u306f\u305d\u3046\u306a\u306e\u304b\u3082\u3057\u308c\u307e\u305b\u3093\u3002\u3057\u304b\u3057\uff0c\u672c\u5f53\u306b\u81a0\u82bd\u816b\u306e\u60a3\u8005\u3055\u3093\u306e\u751f\u547d\u4e88\u5f8c\u3092\u6539\u5584\u3067\u304d\u308b\u304b\u3069\u3046\u304b\u306f\u307e\u3060\u4e0d\u660e\u3067\u3059\u3002<\/p>\n<h4>\u672c\u5eb6\u6559\u6388\u306e\u30ce\u30fc\u30d9\u30eb\u8cde\u53d7\u8cde\u3068\u30aa\u30d6\u30b8\u30fc\u30dc<\/h4>\n<p>2018\u5e7410\u6708\u306e\u5831\u9053\u3067\uff0c\u30aa\u30d6\u30b8\u30fc\u30dc\u304c\u60aa\u6027\u816b\u760d\u306b\u5e83\u7bc4\u56f2\u306b\u6709\u52b9\u3060\u3068\u3044\u3046\u3053\u3068\u304c\u307e\u305f\u5e83\u304f\u5831\u9053\u3055\u308c\u307e\u3057\u305f\u3002\u30aa\u30d6\u30b8\u30fc\u30dc\u306f\uff0c nivolumab \u30cb\u30dc\u30eb\u30de\u30d6\u3068\u3044\u3046\u6297\u4f53\u3067\uff0cT\u7d30\u80de\u7cfb\u3092\u8ce6\u6d3b\u3059\u308b\u514d\u75ab\u6cbb\u7642\u306e\u4e00\u7a2e\u3067\u3059\u3002\u3053\u308c\u306f\u8133\u816b\u760d\u306e\u5206\u91ce\u3067\u3082\uff0c2015\u5e74\u9803\u304b\u3089\u5b66\u4f1a\u767a\u8868\u306a\u3069\u3067\u6ce8\u76ee\u3055\u308c\u307e\u3057\u305f\u304c\u6709\u52b9\u6027\u306f\u8a3c\u660e\u3055\u308c\u307e\u305b\u3093\u3067\u3057\u305f\u3002\u81e8\u5e8a\u8a66\u9a13\u3082\u4e2d\u65ad\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n<h4>DCVax-L\u514d\u75ab\u6cbb\u7642\u306e\u81e8\u5e8a\u7b2c\uff13\u76f8\u8a66\u9a13<\/h4>\n<p>Liau LM, et al.: First\u00a0results\u00a0on\u00a0survival\u00a0from a\u00a0large\u00a0Phase\u00a03\u00a0clinical\u00a0trial\u00a0of an\u00a0autologous\u00a0dendritic\u00a0cell\u00a0vaccine in newly diagnosed glioblastoma. J Transl Med\u00a02018<br \/>\n\u81ea\u5206\u306e\u816b\u760d\u3092\u63a1\u53d6\u3057\u3066\u5206\u89e3\u3057\u3066\uff0c\u305d\u308c\u3067\u6a39\u72b6\u7a81\u8d77\u7d30\u80de\u3092\u523a\u6fc0\u3057\u3066\u4f53\u5185\u306b\u623b\u3059\u3068\u3044\u3046\u514d\u75ab\u6cbb\u7642\u3067\u3059\u3002personalized glioblastoma vaccine \u81a0\u82bd\u816b\u81ea\u5df1\u30ef\u30af\u30c1\u30f3\u3068\u3082\u3044\u3044\u307e\u3059\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u3068\u30c6\u30e2\u30be\u30ed\u30de\u30a4\u30c9\u306e\u5f8c\u3067232\u4eba\u306e\u81a0\u82bd\u816b\u306e\u60a3\u8005\u3055\u3093\u306bDCVax\u304c\u6295\u4e0e\u3055\u308c\u307e\u3057\u305f\u300299\u4eba\u306f\u30c6\u30e2\u30be\u30ed\u30de\u30a4\u30c9\u3092\u7528\u3044\u308b\u6a19\u6e96\u6cbb\u7642\u306e\u307f\u3067\u3059\u304c\uff0c\u518d\u767a\u3057\u305f\u5834\u5408\u306b\u306fDCVaz\u304c\u4f7f\u7528\u3067\u304d\u307e\u3057\u305f\u3002\u7d50\u679c\u7684\u306b90%\u306e\u60a3\u8005\u3055\u3093\u3067DCVax\u304c\u6295\u4e0e\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u4e2d\u9593\u89e3\u6790\u306a\u306e\u3067\u3059\u304c\u751f\u5b58\u671f\u9593\u4e2d\u592e\u5024\u306f23\u30f6\u6708\u306b\u3082\u9054\u3057\uff0c30%\u307b\u3069\u306e\u60a3\u8005\u3055\u3093\u304c3\u5e74\u4ee5\u4e0a\u751f\u5b58\u3057\u3066\u3044\u308b\u3068\u306e\u3053\u3068\u3059\u3002\u307e\u3060\u7d50\u8ad6\u306f\u51fa\u3066\u3044\u307e\u305b\u3093\u304c\uff0c\u5927\u304d\u306a\u526f\u4f5c\u7528\u3082\u306a\u304f\uff0c\u751f\u5b58\u671f\u9593\u306e\u5ef6\u9577\u304c\u5f97\u3089\u308c\u308b\u304b\u3082\u3057\u308c\u306a\u3044\u3068\u3044\u3046\u671f\u5f85\u3092\u3082\u3063\u305f\u5831\u544a\u3067\u3059\u3002<\/p>\n<h4 align=\"left\">\u518d\u767a\u81a0\u82bd\u816b\u306b<strong>\u30aa\u30d7\u30b8\u30fc\u30dc Opdivo (nivolumab)\u306f\u6709\u52b9\u3067\u306f\u306a\u3044<\/strong><\/h4>\n<p align=\"left\">2017\u5e74\u306b\uff0c\u6ce8\u76ee\u306e\u518d\u767a\u81a0\u82bd\u816b\u306b\u5bfe\u3059\u308bOpdivo (nivolumab\uff0cPD-1 checkpoint\u6291\u5236\u5264)\u306e\u7b2c\uff13\u76f8\u8a66\u9a13 CheckMate-143\u306e\u7d50\u679c\u304c\u308f\u304b\u308a\u307e\u3057\u305f\u3002\u751f\u5b58\u671f\u9593\u306e\u5ef6\u9577\u306f\u5f97\u3089\u308c\u307e\u305b\u3093\u3067\u3057\u305f\u3002<\/p>\n<h4>\u305f\u3068\u3048\u30702015\u5e74\u304b\u3089\u59cb\u3063\u305f<strong><span style=\"color: #000080;\">\u5927\u898f\u6a21\u8a66\u9a13 ICT-107<\/span><\/strong><\/h4>\n<p>2015\u5e749\u6708\u306b\uff0c\u7c73\u56fd\u306eNIH\u304c\u8a8d\u53ef\u3057\u305f\u81e8\u5e8a\u7b2c\uff13\u76f8\u8a66\u9a13\u304c\u3042\u308a\u307e\u3059\uff08URL: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02546102)1\u3002\u6b27\u7c73\u3067120\u30ab\u6240\u4ee5\u4e0a\u306e\u65bd\u8a2d\u304c\u53c2\u52a0\u3057\u3066\uff0c24\u5104\u5186\u4ee5\u4e0a\u306e\u8cc7\u91d1\u304c\u6295\u3058\u3089\u308c\u3066\u884c\u308f\u308c\u308b\u3082\u306e\u3067\u3059\u3002<br \/>\nICT-107 consists of dendritic cells, prepared from autologous mononuclear cells that are pulsed with six synthetic peptides that were derived from tumor associated antigens (TAA) present on glioblastoma tumor cells. This is a Phase 3 study to evaluate ICT-107 in patients with newly diagnosed glioblastoma. Subjects will be randomized to receive standard of care chemoradiation (temozolomide (TMZ) with either ICT-107 or a blinded control. Reinfusion with the pulsed dendritic cells should stimulate cytotoxic T cells to specifically target glioblastoma tumour cells. \u7c21\u5358\u306b\u8a33\u3059\u3068\uff0c<span style=\"color: #000080;\"><strong>\u81a0\u82bd\u816b\u306b\u767a\u73fe\u3057\u3066\u3044\u308b\u816b\u760d\u95a2\u9023\u6297\u539f\u304b\u3089\u9078\u3093\u3060\uff16\u7a2e\u985e\u306e\u30da\u30d7\u30c1\u30c9\u86cb\u767d<\/strong><\/span>\u3067\uff0c\u60a3\u8005\u3055\u3093\u306e\u672b\u68a2\u8840\u304b\u3089\u5206\u96e2\u3057\u305f\u5358\u6838\u7403\u3092\u523a\u6fc0\u3057\u3066\uff0c<strong><span style=\"color: #000080;\">\u6a39\u72b6\u7a81\u8d77\u7d30\u80de<\/span><\/strong>\u306b\u3057\u305f\u3082\u306e\u3092ICT-107\u3068\u547c\u3073\u307e\u3059\u3002\u305d\u308c\u3092\u60a3\u8005\u3055\u3093\u306e\u4f53\u5185\u306b\u3082\u3069\u3059\u3068\uff0c\u6a39\u72b6\u7a81\u8d77\u7d30\u80de\u304cT\u7d30\u80de\uff08\u30ea\u30f3\u30d1\u7403 CTL\uff09\u3092\u3055\u3089\u306b\u523a\u6fc0\u3057\u3066\uff0c\u305d\u306eT\u30ea\u30f3\u30d1\u7403\u304c\u81a0\u82bd\u816b\u306e\u7d30\u80de\u3092\u653b\u6483\u3059\u308b\u3068\u3044\u3046\u7406\u8ad6\u3067\u3059\u3002<br \/>\n\u300c\u89e3\u8aac\u300d\u3053\u306e\u7814\u7a76\u306f2018\u5e74\u304f\u3089\u3044\u3067\u5148\u304c\u898b\u3048\u308b\u304b\u3082\u3057\u308c\u307e\u305b\u3093\u3002\u3067\u3082\u540c\u3058\u3088\u3046\u306a\u7814\u7a76\u304c\u4eca\u307e\u3067\u4f55\u5ea6\u3068\u306a\u304f\u306a\u3055\u308c\u3066\u5931\u6557\u306b\u7d42\u308f\u3063\u305f\u3068\u3044\u3046\u3053\u3068\u3082\u3042\u308a\u307e\u3059\u3002\u306f\u3063\u304d\u308a\u3057\u305f\u7d50\u679c\u304c\u51fa\u3055\u308c\u308b\u307e\u3067\uff0c\u6a39\u72b6\u7a81\u8d77\u7d30\u80de\u304c\u6709\u52b9\u3067\u3042\u308b\u3068\u306f\u6c7a\u3057\u3066\u8a00\u3048\u307e\u305b\u3093\u3002\u307e\u3057\u3066\uff0c\u65e5\u672c\u306e\u5404\u5927\u5b66\u3067\u5358\u767a\u7684\u306b\u884c\u308f\u308c\u3066\u3044\u308b\u6975\u5c0f\u898f\u6a21\u306e\u5b9f\u9a13\u7684\u4f7f\u7528\u306e\u7d50\u679c\u3092\u4fe1\u3058\u308b\u3053\u3068\u306f\u3067\u304d\u307e\u305b\u3093\u3002<\/p>\n<h4>rindopepimut \u30ef\u30af\u30c1\u30f3\u306e\u4e2d\u6b62<\/h4>\n<p>Schuster J, et al.: A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol 17: 854-861, 2015<br \/>\n\u81a0\u82bd\u816b\u3067\u306fEGFR\uff08epidermal grwoth factor\u00a0\u53d7\u5bb9\u4f53\uff09\u306e\u5909\u7570\u306e\u983b\u5ea6\u304c\u9ad8\u3044\u3053\u3068\u304c\u77e5\u3089\u308c\u3066\u3044\u307e\u3057\u305f\u30023\u5272\u307b\u3069\u306e\u81a0\u82bd\u816b\u306fEGFRvIII\u3092\u767a\u73fe\u3057\u3066\u3044\u3066\uff0c\u305d\u306e\u30bf\u30a4\u30d7\u306e\u4e88\u5f8c\u304c\u60aa\u3044\u3068\u3055\u308c\u3066\u3044\u307e\u3059\u3002rindopepimut\u306f<strong><span style=\"color: #ff0000;\">EGFRvIII\u7531\u6765\u306e\u30da\u30d7\u30c1\u30c9<\/span><\/strong>\u3067\uff0c\u30ef\u30af\u30c1\u30f3\u3068\u3057\u3066\u7528\u3044\u3089\u308c\u307e\u3059\u3002\u3053\u306e\u5831\u544a\u306f\uff0cEGFRvIII\u3092\u767a\u73fe\u3057\u3066\u3044\u308b\u81a0\u82bd\u816b\u306b\u5bfe\u3057\u3066\u306erindopepimut\u306e\u52b9\u679c\u3092\u591a\u65bd\u8a2d\u81e8\u5e8a\u7b2c2\u76f8\u8a66\u9a13\u3067\u307f\u305f\u3082\u306e\u3067\u3059\u300265\u4eba\u306e\u60a3\u8005\u3055\u3093\u306b\u6295\u4e0e\u3055\u308c\uff0c\u751f\u5b58\u671f\u9593\u4e2d\u592e\u502421.8\u30f6\u6708\u3068\u3044\u3046\u826f\u3044\u6210\u7e3e\u304c\u3067\u307e\u3057\u305f\u30022015\u5e74\uff0c<span style=\"color: #000080;\"><strong><a style=\"color: #000080;\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01480479\">\u81e8\u5e8a\u7b2c3\u76f8\u8a66\u9a13 (ACT IV)<\/a><\/strong><\/span>\u304c\u884c\u308f\u308c\u307e\u3057\u305f\u3002\u5168\u6458\u51fa gross total removal\u3067\u304d\u305f\u81a0\u82bd\u816b\u3067EGFRvIII\u3092\u767a\u73fe\u3057\u3066\u3044\u308b400\u75c7\u4f8b\u304c\u5bfe\u8c61\u3068\u306a\u308a\u307e\u3057\u305f\u3002<br \/>\n\u300c\u7d50\u679c\u300d\u5168\u751f\u5b58\u5272\u5408\u3067\u512a\u4f4d\u6027\u304c\u306a\u304f\uff0c2016\u5e743\u6708\u306b\u3053\u306e\u8a66\u9a13\u306f\u4e2d\u6b62\u3055\u308c\u307e\u3057\u305f\u3002<\/p>\n<h4 align=\"left\">\u30b5\u30a4\u30c8\u30e1\u30ac\u30ed\u30a6\u30a3\u30eb\u30b9\u6297\u539f\u3068\u6a39\u72b6\u7a81\u8d77\u7d30\u80de<\/h4>\n<p>Mitchell DA, et al.: Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. <strong><span style=\"color: #ff0000;\">Nature<\/span><\/strong> 519: 366\u2013369, 2015<br \/>\ntumor-antigen-specific dendric cells (DC, \u816b\u760d\u6297\u539f\u7279\u7570\u7684\u6a39\u72b6\u7a81\u8d77\u7d30\u80de)\u3092\u4f7f\u3063\u305f\u514d\u75ab\u6cbb\u7642\u306e\u5831\u544a\u3067\u3059\u3002<i>Cytomegalovirus<\/i>\u00a0phosphoprotein 65 (pp65)\u304c\u81a0\u82bd\u816b\u306e90%\u4ee5\u4e0a\u306b\u767a\u73fe\u3057\u3066\u3044\u308b\u3068\u3044\u3046\u3053\u3068\u304b\u3089\uff0c\u3053\u306e\u6297\u539f\u304c\u81a0\u82bd\u816b\u306e\u816b\u760d\u7279\u7570\u6297\u539f\u3067\u3042\u308b\u3068\u3044\u3046\u4eee\u8aac\u306b\u57fa\u3065\u3044\u3066\uff0cpp65 RNA\u3067\u611f\u4f5c\u3057\u305f\u6a39\u72b6\u7a81\u8d77\u7d30\u80de\u304c\u7528\u3044\u3089\u308c\u307e\u3057\u305f\u3002\u540c\u6642\u306btetanus\/diphtheria (Td) toxoid\u304cDC\u6295\u4e0e\u524d\u51e6\u7f6e\u3055\u308c\u3066\u3044\u307e\u3059\u300213\u4eba\u306e\u60a3\u8005\u3055\u3093\u304c\u7121\u4f5c\u70ba\u306b\u5206\u5225\u3055\u308c\uff0cTd\u51e6\u7406\u3055\u308c\u305fRTOG-RPA (recursive partitioning analysis) class IV\uff08predicted 11 mos)\u00a06\u4eba\u306e\u60a3\u8005\u3055\u3093\u3067\u306f\uff0c\u4e2d\u592e\u502418\u30f6\u6708\u4ee5\u4e0a\u306e\u751f\u5b58\u671f\u9593\u304c\u5f97\u3089\u308c\u305f\u3068\u306e\u3053\u3068\u3067\u3059\u3002<br \/>\n\u300c\u89e3\u8aac\u300d\u5927\u304d\u306a\u671f\u5f85\u304c\u6301\u3066\u305d\u3046\u306a\u514d\u75ab\u6cbb\u7642\u306e\u5831\u544a\u306f\u3053\u306e40\u5e74\u9593\u3067\u4f55\u5ea6\u3082\u4f55\u5ea6\u3082\u73fe\u308c\u305f\u3082\u306e\u3067\u3059\u3002\u3057\u304b\u3057\uff0c\u73fe\u5b9f\u7684\u306b\u81e8\u5e8a\u5fdc\u7528\u3067\u304d\u308b\u3082\u306e\u306f\u3042\u308a\u307e\u305b\u3093\u3067\u3057\u305f\u3002Nature\u3068\u3044\u3046\u6a29\u5a01\u3042\u308b\u96d1\u8a8c\u306b\u63b2\u8f09\u3055\u308c\u305f\u306e\u3067\u3059\u304c\uff0c\u540c\u69d8\u306a\u7d50\u679c\u304c\u591a\u6570\u4f8b\u3067\u8ffd\u8a66\u78ba\u8a8d\u3055\u308c\u306a\u3044\u3068\u4fe1\u3058\u308b\u3053\u3068\u306f\u3067\u304d\u307e\u305b\u3093\u3002<br \/>\n\u300c\u7d50\u679c\u300d2017\u5e74\u306e\u5831\u544a\u3067\u306f\u30b5\u30a4\u30c8\u30e1\u30ac\u30ed\u30a6\u30a3\u30eb\u30b9\u3068\u81a0\u82bd\u816b\u306b\u95a2\u9023\u306f\u306a\u3044\u3068\u7d50\u8ad6\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u4ed6\u306e\u5831\u544a\u3067\uff0c122\u4f8b\u306e\u661f\u7d30\u80de\u7cfb\u816b\u760d\u306e\u30b5\u30f3\u30d7\u30eb\u306b\u3082\u898b\u51fa\u3055\u308c\u307e\u305b\u3093\u3067\u3057\u305f\u3002<\/p>\n<h4><span class=\"highlight\">WT-1<\/span>\u00a0\u30da\u30d7\u30c1\u30c9\u30ef\u30af\u30c1\u30f3\u3000(Wilms&#8217; tumor gene-1) peptide vaccine<\/h4>\n<p>Izumoto S, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.\u00a0<span class=\"ref-journal\">J Neurosurg.\u00a0<\/span>2008<br \/>\nHashimoto N, et al. Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.\u00a0<span class=\"ref-journal\">Cancer Immunol Immunother.\u00a0<\/span>2015<br \/>\n\u65e5\u672c\u306710\u5e74\u4ee5\u4e0a\u4f7f\u7528\u3055\u308c\u3066\u3044\u308b\u30ef\u30af\u30c1\u30f3\u3067\uff0c\u4e3b\u3068\u3057\u3066\u5c0f\u5150\u8133\u816b\u760d\u306b\u6709\u52b9\u3060\u3068\u3055\u308c\u3066\u304d\u307e\u3057\u305f\u3002\u591a\u304f\u306e\u65e5\u672c\u306e\u60aa\u6027\u8133\u816b\u760d\u306e\u5b50\u3069\u3082\u305f\u3061\u304c\u3053\u306e\u6cbb\u7642\u3092\u53d7\u3051\u305f\u3068\u601d\u3044\u307e\u3059\u3002\u3067\u3082\u7d50\u679c\u304c\u516c\u8868\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002\u7d50\u679c\u304c\u51fa\u306a\u3044\u3068\u3044\u3046\u3053\u3068\u306f\u300c\u6709\u52b9\u304b\u3082\u7121\u52b9\u304b\u3082\u3057\u308c\u306a\u3044\u300d\u306e\u3067\uff0c\u300c\u6709\u52b9\u304b\u3082\u3057\u308c\u306a\u3044\u300d\u3068\u3044\u3046\u671f\u5f85\u306e\u4e0a\u306b\u4f7f\u7528\u3057\u7d9a\u3051\u308b\u3068\u3044\u3046\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002\u300c\u7121\u52b9\u300d\u3060\u3068\u3044\u3046\u7d50\u679c\u304c\u51fa\u308b\u3053\u3068\u3088\u308a\u300c\u4e0d\u660e\u300d\u306e\u307e\u307e\u4f7f\u7528\u3055\u308c\u308b\u3053\u3068\u306e\u65b9\u304c\u6050\u308d\u3057\u3044\u3068\u601d\u3044\u307e\u3059\u3002\u5b66\u8853\u8a8c\u3067\u306f\u306a\u3044\u30cd\u30c3\u30c8\u3067\u306f\u4f55\u3067\u3082\u66f8\u3051\u308b\u306e\u3067\uff0c2016\u5e74\u6642\u70b9\u306e\u8a18\u4e8b\u3067\u3082\u300cWT1\u30da\u30d7\u30c1\u30c9\u30ef\u30af\u30c1\u30f3\u306f\uff0c\u96e3\u6cbb\u6027\u3068\u3044\u308f\u308c\u308b\u30b0\u30ea\u30aa\u30d6\u30e9\u30b9\u30c8\u30fc\u30de\u306e\u81e8\u5e8a\u306b\u304a\u3044\u3066\u9a5a\u7570\u7684\u306a\u6cbb\u7642\u6210\u7e3e\u3092\u3042\u3052\u3066\u3044\u307e\u3059\u3002\u300d\u3068\u66f8\u3044\u3066\u3042\u308a\u307e\u3057\u305f \uff01(\u25ce_\u25ce;)<\/p>\n<p style=\"text-align: center;\"><a href=\"\/sawamura\/blog\/wp-content\/uploads\/2013\/01\/snakeimmuno.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-1978\" title=\"snakeimmuno\" src=\"\/sawamura\/blog\/wp-content\/uploads\/2013\/01\/snakeimmuno.jpg\" alt=\"\" width=\"567\" height=\"464\" \/><\/a><\/p>\n<p>\u3053\u306e\u30da\u30fc\u30b8\u306b\u3053\u306e\u5199\u771f\u3092\u51fa\u3059\u306e\u306f\u504f\u898b\u304b\u3082\u3057\u308c\u306a\u3044\u306e\u3067\u3059\u304c&#8212;\uff08\uff0d_\uff0d\uff09<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u6628\u4eca\u306eNHK\u306e\u5831\u9053\u306a\u3069\u306e\u5f71\u97ff\u3067\uff0c\u305f\u304f\u3055\u3093\u306e\u304c\u3093\u60a3\u8005\u3055\u3093\u304c\u514d\u75ab\u6cbb\u7642\u3092\u6c42\u3081\u308b\u3088\u3046\u306b\u306a\u308a\u307e\u3057\u305f\u3002\u307e\u305f\uff0c\u96d1\u8a8c\u3084\u30cd\u30c3\u30c8\u4e0a\u3067\u3082\uff0c\u514d\u75ab\u6cbb\u7642\u3092\u53d7\u3051\u308b\u3053\u3068\u306b\u3088\u3063\u3066\u304c\u3093\u306e\u9032\u884c\u3092\u6b62\u3081\u308b\u3053\u3068\u304c\u3067\u304d\u3066\uff0c\u3064\u3089\u3044\u5236\u304c\u3093\u5264\u306e\u5316\u5b66\u7642\u6cd5\u304b\u3089\u89e3\u653e\u3055\u308c\u3066\uff0c\u65e5\u5e38 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-1977","post","type-post","status-publish","format-standard","hentry","category-glioma"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/blog\/wp-json\/wp\/v2\/posts\/1977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/blog\/wp-json\/wp\/v2\/comments?post=1977"}],"version-history":[{"count":39,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/blog\/wp-json\/wp\/v2\/posts\/1977\/revisions"}],"predecessor-version":[{"id":23109,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/blog\/wp-json\/wp\/v2\/posts\/1977\/revisions\/23109"}],"wp:attachment":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/blog\/wp-json\/wp\/v2\/media?parent=1977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/blog\/wp-json\/wp\/v2\/categories?post=1977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/blog\/wp-json\/wp\/v2\/tags?post=1977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}